Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).

Sponsor
National Multiple Sclerosis Center (Other)
Overall Status
Terminated
CT.gov ID
NCT04295616
Collaborator
National MS Center Melsbroek (Other)
5
1
2
6.2
0.8

Study Details

Study Description

Brief Summary

This study aims to investigate whether intrapulmonary percussive ventilation (IPV) in combination with active breathing exercises using the flow-based incentive spirometer (Inspirix) has a positive effect on the respiratory values in people with multiple sclerosis (MS).

Condition or Disease Intervention/Treatment Phase
  • Device: Intrapulmonary percussive ventilation (IPV)
  • Behavioral: Active breathing training
N/A

Detailed Description

The primary research question includes "what is the additional effect of intensive IPV treatment in combination with active breathing exercises on respiratory power (Peak Expiratory Flow, PEF) in people with MS?".

In a single-center randomized clinical trial, 96 people with MS-related respiratory problems will be allocated to either the intervention group (IPV + active breathing training) or the control group (active breathing training only). Interventions will be provided by trained speech- and language therapists, in combination with a multidisciplinary rehabilitation programme of 3 weeks. Pre- en posttraining assessment includes measures of respiration, speech and fatigue.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
The Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).
Actual Study Start Date :
Jan 13, 2020
Actual Primary Completion Date :
Jul 20, 2020
Actual Study Completion Date :
Jul 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: IPV & active breathing training

Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.

Device: Intrapulmonary percussive ventilation (IPV)
IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute. Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks.

Behavioral: Active breathing training
The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.

Active Comparator: Active breathing training only

Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.

Behavioral: Active breathing training
The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in breathing force [pre- post (3 weeks) (some participants also at 4 weeks)]

    Change in Peak Expiratory Flow (PEF)- Maximum flow achieved during a maximum forced exhalation.

Secondary Outcome Measures

  1. Change in Pulmonary Dysfunction Index (PDI) [pre- post (3 weeks) (some participants also at 4 weeks)]

    To determine the PDI, the assessor judges the cough force and the ability of the person to count on 1 exhalation. PDI scores vary between 4 and 11 and a higher score indicates increasing respiratory difficulties.

  2. Change in Maximum Phonation time (MFT) [pre- post (3 weeks) (some participants also at 4 weeks)]

    The maximum phonation time (MFT) (in seconds) is measured at a comfortable pitch of the voice. The patient is instructed to breathe in as deeply as possible and to hold / a / as long as possible. MFT is measured three times and the longest value is retained.

  3. Change in Voice Handicap Index (VHI-10) [pre- post (3 weeks) (some participants also at 4 weeks)]

    The Voice Handicap Index (VHI-10) 10-item questionnaire assesses the psychosocial impact on the voice as perceived by the individual. The VHI-10 scores range from 0 to 40, with increasing scores indicating increased psychosocial impact. A score of 11 or higher implies a voice handicap.

  4. Change in Vital Capacity (VC) [pre- post (3 weeks) (some participants also at 4 weeks)]

    Maximum amount of air that is exhaled after a deep inhalation. The person is asked to breathe out as deeply as possible in the mouthpiece after a deep inhalation.

  5. Change in Maximum Inspiratory Pressure (MIP) [pre- post (3 weeks) (some participants also at 4 weeks)]

    Maximum inspiratory pressure at which the person inhales against a resistance.

  6. Change in Maximum Expiratory Pressure (MEP) [pre- post (3 weeks) (some participants also at 4 weeks)]

    MEP is the highest pressure that arises during a powerful exhalation against a resistance.

  7. Change in Visual Analogue Scale (VAS) for fatigue [pre- post (3 weeks) (some participants also at 4 weeks)]

    This is an assessment instrument consisting of a straight line of 10 cm with two opposite statements at both ends. On the left is the statement "not at all tired" and on the right "extremely tired".

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis MS

  • inpatient in the National Multiple Sclerosis Center Melsbroek for at least 3 weeks in the period Jan-Dec 2020

  • adequate lip closure

  • adequate cognitive functioning (MMSE>26/30 & clinical observation)

  • Peak Expiratory Flow (PEF) with a cut off score of 80% or lower

Exclusion Criteria:
  • IPV or other breathing treatment of more than 1x/week within 3 months prior to study participation

  • MS relapse within 3 months prior to study participation

  • asthma or Chronic Obstructive Pulmonary Disease (COPD)

  • infection of lower respiratory tract within 6 weeks prior to study participation

  • infection of upper respiratory tract within 2 weeks prior to study participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 National MS Center Melsbroek Belgium 1820

Sponsors and Collaborators

  • National Multiple Sclerosis Center
  • National MS Center Melsbroek

Investigators

  • Principal Investigator: Sofie NoĆ«, Msc, National MS Center Melsbroek - Speech and Language Therapy

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
National Multiple Sclerosis Center
ClinicalTrials.gov Identifier:
NCT04295616
Other Study ID Numbers:
  • S 501553
First Posted:
Mar 4, 2020
Last Update Posted:
Aug 5, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2020